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Aim: To investigate whether concomitant treatment with clopidogrel and proton pump inhibitors (PPIs) worsens clinical outcome in patients with 
coronary artery disease.
Methods: We undertook a meta-analysis of combined major adverse cardiovascular events (MACE), myocardial infarction and death in 14 
clopidogrel studies (57,100 patients: 3 randomised trials, 11 non-randomised studies) comparing patient with and without PPI use (25,179 vs. 
31,921).
Results: Concomitant PPI use was not associated with a worse outcome in randomised studies (risk ratio for MACE RR=1.03; CI=0.89-1.18; 
p=0.71). In contrast, non-randomised concomitant PPI use was associated with a 56% relative risk increase in MACE (RR=1.56; CI=1.47-1.64; 
p<0.001), a 73% relative risk increase to develop myocardial infarction (RR=1.73; CI=1.58-1.90; p<0.001) and an 18% relative risk increase of 
death (RR=1.18; CI=1.07-1.29; p<0.001). However, patients on PPIs were 1.5 years older and suffered more frequently from co-morbidities such as 
diabetes mellitus (RR=1.24; CI=1.16-1.32; p<0.001), renal insufficiency (RR=1.63; CI=1.48-1.79; p<0.001), heart failure (RR=1.62; CI=1.49-1.77; 
p<0.001), previous myocardial infarction (RR=1.25; CI=1.15-1.35; p<0.001), hypertension (RR=1.14; CI=1.03-1.26; p=0.01) and cancer (RR=1.35; 
CI=1.13-1.61; p=0.001), respectively. The pooled analysis showed that patients on concomitant treatment with PPIs had 1.34 fold overall more 
co-morbidities compared to patients without PPI (RR=1.34; CI=1.29-1.39; p<0.001). Interestingly, concomitant PPI use was not associated with an 
increase in the risk of MACE in patients treated with clopidogrel compared to controls (placebo or prasugrel; RR=1.04; CI=0.86-1.25; p<0.71).
Conclusions: A higher rate of co-morbidities in patients with concomitant PPI medication might be the major cause for the observed worse clinical 
outcome in patients with cardiovascular disease and clopidogrel treatment, rather than the PPI use itself.
